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Abstract  
Mesenchymal stem cells (MSCs), also known as stromal mesenchymal stem cells, are 
multipotent cells, which can be found in many tissues and organs as bone marrow, adipose tissue 
and other tissues. In particular MSCs derived from Adipose tissue (ADSCs) are the most 
frequently used in regenerative medicine because they are easy to source, rapidly expandable in 
culture and excellent differentiation potential into adipocytes, chondrocytes and other cell types.  
Acetylcholine (ACh), is one of the most important neurotransmitter in central (CNS) and 
peripheral nervous system (PNS), playing important roles also in non-neural tissue, but its 
functions in MSCs are still not investigated. Although MSCs express muscarinic receptor 
subtypes, their role is completely unknown.  
In present work muscarinic cholinergic effects were characterized  in rat ADSCs. Analysis by 
RT-PCR demonstrates that ADSCs express M1-M4 muscarinic receptor subtypes, whereas M2 is 
one of the most expressed subtype. For this reason, our attention was focused on M2 subtype. By 
using the selective M2 agonist Arecaidine Propargyl Ester (APE) we performed cell proliferation 
and migration assays demonstrating that APE causes cell growth and migration inhibition 
without affecting cell survival. Our results indicate that ACh via M2 receptors, may contribute to 
the maintaining of the ADSCs quiescent status. These data are the first evidence that ACh via 
muscarinic receptors might contribute to control ADSCs physiology. This article is protected by 
copyright. All rights reserved 
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Introduction 
All tissues have hierarchical cellular organization; these include a small number of stem cells 
and differently derived cell types. Stem cells are immature precursor cells, unspecialized, with 
ability to perpetuate themselves (self-renewal), maintaining the same undifferentiated stage and 
the potential to generate mature cells through asymmetric division. Through this process, stem 
cells generate one stem and one daughter cell, with specific fate. Stem cells are quiescent cells 
(in G0 phase) or characterised by a slow proliferation rate and normally they are maintained in 
an undifferentiated state until they are required to support physiological cell turnover. Stem cells 
are also able to divide through symmetrical division, leading to the formation of two daughter 
cells with identical self-renewal capacity, maintaining the stem cell pool. Thereby, stem cells can 
differentiate in specialised cells (Weissman, 2000). The asymmetric division allows to control 
the stem cell number in the tissue, which may remain constant at least during the adult life. 
Notably, the low replication rate reduces the probability to accumulate DNA damage and 
mutations (Ilic et al, 2011).  
There are various types of stem cells, whose identity is determined by their origin and 
differentiative potential, such as totipotent cells, pluripotent cells, unipotent stem cells. 
Mesenchymal stromal cells (MSCs) derived from the mesoderm, the middle germ layer that 
during embryogenesis originates different tissues and cells, such as connective, condrocytes, 
bone, endotelial and muscle cells. MSCs can also interact with hematopoietic stem cells (HSCs), 
giving rise to immunomodulatory mechanisms (Chamberlain et al, 2007). Bone marrow stem 
cells have been widely proposed and used in regenerative medicine as source of MSCs 
(Caddick et al, 2006). Giving their high invasive procedure of collection, in the last decade some 
criticisms were raised about their use. For instance, it has been observed low cell proliferation 
with slow ex vivo expansion and incresed senescence, directly correlated to the age of the donor 
(Caddick et al, 2006). For these reasons, the identification of an alternative source of MSCs is 
required.  
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Adipose tissue is constituted by small blood vessels, nerve cells, fibroblasts, as well as by 
adipocyte progenitors, known as pre-adipocytes or adipose derived mesenchymal stem cells 
(ADSCs) (Vindigni et al, 2013). ADSCs can be easily isolated by conventional liposuction, a 
less invasive procedure compared to the bone marrow sampling (Kingham et al, 2007). 
In vitro ADSCs share many characteristic features of Bone Marrow MSCs: stickiness to plastic, 
fibroblastoid morphology and potential differentiative capacity under appropriate conditions, 
into osteoblasts, adipocytes and chondroblasts (Strem et al, 2005; Frith et al, 2008). MSCs can be 
easily isolated: they are positive for a lot of specific markers, such as the antigens CD105, CD73, 
CD44, CD29 and CD90. Contemporarily, MSCs are negative for the antigens CD45, CD34, 
CD14, CD11b, CD79a, CD19 and HLA-DR (Strem et al, 2005; Bobis et al, 2006).  
ADSCs possess the typical stem cells ultrastructure, including the high nucleus/cytosol ratio, 
exhibit prominent nucleoli and numerous cytoplasmic organelles (Patel et al, 2013; Ryu et al, 
2013). 
In general, ADSCs are easy to source and present lack of immunogenicity, enabling allogenic 
transplantation without the use of immunosuppressive drugs. Moreover, the lack of ethical 
controversies make them of potential interest in tissue-specific differentiation (Grimble et al, 
2007; Karp et al, 2009). ADSCs possess multi-differentiate properties and act as a "secretome",  
releasing proteins and growth factors in the extracellular matrix (ECM), with a high impact on 
the different organs and systems (Vindigni et al, 2013). For all these properties, ADSCs appear a 
good cell candidate in the field of regenerative medicine and gene therapy.  
In recent years, the scientific community consolidated the concept of the presence of a non-
neuronal cholinergic system, whose first demonstration has been described in the placenta 
(Morris, 1966). The cholinergic system is expressed in the skin, in the respiratory and immune 
system, where it is involved in the proliferation, differentiation and survival/apoptosis of 
different cell types (Skok et al, 2006; Hoogduijn et al, 2009). MSCs are  regulated by a variety of 
intracellular and extracelluar signals such as BMPs, Notch, Wnt, IFNȖ and many other signaling 
pathways not yet identified (Hoogduijn et al, 2009). The widespread expression of the 
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cholinergic system in non-neuronal tissues has suggested that the specific neurotransmitter 
acetylcholine (ACh) may have a role in the regulation of cell physiology in different cell types 
(Wessler et al, 1999). In this light, it has been recently shown that the nicotinic receptor 
stimulation in embryonic mouse stem cells regulates Oct-4 and Rex-1 markers (Zhang et al, 
2015). In mammals, however, the cholinergic system achieves the full maturation after birth 
(Berger-Sweeney et al, 1997), suggesting that this system may play important role in adult stem 
cells. Moreover, more recent evidence reported the presence of ACh in different stem cell niches 
including hippocampal dentate gyrus subgranular zone (SGZ) and in lateral ventricular zone 
(LV) of the mammalian brain, suggesting that cholinergic signals may contribute to the 
modulation of  adult neural stem cell physiology (Asrican et al, 2016).  Interestingly, MSCs have 
also the ability to produce ACh, having a positive staining for ChAT (Hoogduijn et al, 2009). 
However, no clear evidence on the role of ACh in ADSCs has been described, nonetheless a full 
characterization of muscarinic and/or nicotinic receptor subtypes in ADSCs was performed 
(Hoogduijn et al, 2009).     
In this study, using stem cells isolated from rat adipose tissue, the role of ACh and muscarinic 
receptors was investigated in ADSCs development and physiology. In detail, the muscarìnic 
receptor subtypes expressed has been characterized in ADSCs, focusing on the effects produced 
by the selective activation of M2 subtype, whose ability to modulate cell proliferation and 
differentiation has been previously described in different cell types (De Angelis et al, 2012; 
Uggenti et al, 2014; Alessandrini et al 2015). The results obtained demonstrate that ADSCs cell 
proliferation and migration are affected by M2 selective activation. 
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Material and Methods 
 
Adipose derived stem cells 
ADSCs were kindly provided by Professor Reid, University of Manchester, UK. However 
ADSCs were isolated from adult Sprague-Dawley rats as previously described (Kingham et al, 
2007). Subcutaneous, visceral and inguinal fat pads were passed through a 100μm cell strainer 
after mechanical and enzymatic dissociation with collagenase type I (Life technologies, Monza, 
Italy). The resulting cell suspensions were pelleted by 5 min of centrifugation at 900 rpm, 
resuspended in α-MEM plus 10% (v/v) FBS (Sigma-Aldrich, St. Louis, MO, USA) and plated 
onto 75 cm2 flasks. When confluent, cells were detached with trypsin-EDTA (Life Technologies, 
Monza, Italy). The cells were mantained in α-MEM (Sigma-Aldrich, St. Louis, MO, USA) 
containig 10% (v/v) FBS (Sigma-Aldrich, St. Louis, MO, USA) and 1% Penicillin/Streptomycin 
solution (Sigma-Aldrich, St. Louis, MO, USA). Cultures was mainteined at sub-confluent levels 
at 37°C in umidified atmosphere with 5%CO2-95% air.  
 
Cell treatments 
The cells were treated with M2 muscarinic receptor agonist, Arecaidine Propargyl Ester 
hydrobromide (APE, Sigma-Aldrich, St. Louis, MO, USA) at the final concentration of 100µM. 
The APE selectivity for M2 receptors was largely confirmed by siRNA transfection for M2 
receptors and by pharmacological binding experiments (Alessandrini et al, 2015). According 
previous experiments, muscarinic antagonists were used at the final concentration of 10-7M for 
Methoctramine (M2 antagonist, Sigma-Aldrich, St. Louis, MO, USA), 10-7M for Pirenzepine 
(M1 antagonist Sigma-Aldrich, St. Louis, MO, USA) and 10-8M for 4-DAMP (M3 antagonist 
Sigma-Aldrich, St. Louis, MO, USA), (Ferretti et al, 2013, Alessandrini et al, 2015). The cells 
were treated with muscarinic receptor antagonist 2h before APE treatment. 
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RT-PCR analysis 
Total RNA was extracted using Tri-Reagent (Sigma-Aldrich, St. Louis, MO, USA) and digested 
with DNAseI (Ambion-Life technologies Italia, Monza, Italy). Two µg of total RNA was reverse 
transcripted into cDNA with 1µg of random Primers (Promega, Madison, WI, USA) and 200U 
of Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Promega Madison, WI, 
USA). Glyceraldehyde-3-phospate dehydrogenase (GAPDH) was used as the housekeeping 
gene. The sequences of the primers used in RT-PCR analysis are reported in Table 1.  
 
Western Blot 
Protein samples were extracted in Lysis buffer (10nM Tris, 0,5% NP40, 150mM NaCl). Sample 
buffer (4X) was added to the protein sample, heated for 5 minutes at 100°C and then loaded onto 
a 10% SDS polyacrylamide gel and run at 30mA using running buffer (25 mM Tris, 190 mM 
glycine, 0,08% (w/v) SDS). SDS-PAGE gels were transferred for 2h onto PVDF membranes 
(Millipore, Billerica, MA) at 200 mA in transfer buffer (20mM Tris; 150 mM glycine, 10% (v/v) 
methanol). After 5% non-fat dry milk block (Cell Signalling Technology, Davers MA, USA), the 
membranes were incubated overnight at 4°C, with the primary antibody, previously diluted in the 
blocking solution.The mouse anti-M2 primary antibody (1:500; Abcam, UK RRID:AB_303318), 
mouse anti-PCNA (1:700; Sigma-Aldrich, St. Louis, MO, USA, RRID:AB_1842895); rabbit 
anti-CXCR4 (1:300; Novusbio, UK; RRID:AB_10001320) and rabbit anti-CXCR7 (1:300; 
Abcam,UK; RRID:AB_880133) were used. Actin was used as protein reference (anti-actin, 
1:6000, Millipore, Milan; RRID:AB_223041). Membranes were incubated with HPR-conjugated 
secondary antibody (1:20000, Promega, Madison, WI, USA). Protein expression was detected by 
using enhanced chemiluminescence (ECL) (Euroclone, Pero, MI, Italy). 
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 Immunocytochemistry 
ADSCs were plated onto 12 multiwells in complete medium (α-MEM containig 10% FBS and 
1% Penicillin/Streptomycin solution) (Sigma-Aldrich, St. Louis, MO, USA). The following day, 
cells were treated as required by experimental plan. Then they were washed with PBS twice and 
fixed with 4% paraformaldehyde in PBS for 20 min at room temperature (RT). After three 
washes in PBS, the cells were pre-incubated in PBS solution containing 0.1% Triton X-100 and 
10% normal goat serum (NGS) for 1 h at RT. Then cells were incubated with a monoclonal anti-
M2 antibody (1:200, Abcam, UK, RRID:AB_303318) at 4 °C overnight. The next day, the cells 
were washed with PBS three times for 10 min. After washes, cells were incubated with goat anti-
mouse IgG-Alexa 594 conjugated  (Promega Italia, MI, Italy) (diluted 1:500 in PBS+ 0.1% 
Triton X-100 + 1% NGS) for 2 h at RT. After three washes in PBS, the slides were mounted 
with Vectashield (H1200, Vector Lab, DBA, Milan, Italy). 
 
 Migration  assays 
To evaluate cell migration, the wound healing and the Boyden chamber assays were  used.  
For wound healing assay the cells were plated on 60 mm2   dishes and then treated with 100μM 
APE (Sigma-Aldrich, St. Louis, MO, USA) for 6h. Cells were treated with muscarinic receptor 
antagonist (Methoctramine 10-7M, Pirenzepine 10-7M and 4-DAMP 10-8M) (Sigma-Aldrich, St. 
Louis, MO, USA), 2h before APE treatment. The scratch was made up with p200 tip, then the 
Mitomicin C (50ng/ml, Sigma-Aldrich, St. Louis, MO, USA) was added to the culture medium, 
to exclude a possible influence of cell proliferation. The cells were photographed at the start (t0) 
and after 6h (t6). The space between the two fronts at the start and after 6h was then measured. 
The two values were subtracted (t0-t6), obtaining the covered space by the cells in the 
experimental time chosen. 
Migration was also tested by Boyden’s assay, using a 48-well chamber, according to 
manufacturer's instructions (Neuroprobe, Cabin John, MD, USA). Cells were treated with 
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100µM APE, as described above. DMEM/1%FBS  was placed in the lower compartment of the 
chamber, as chemo-attractant. The open-bottom wells of the upper compartment were filled with 
cells (105cells/well), collected by trypsin and suspended in DMEM + 0.1 % bovine serum 
albumin (BSA, Sigma). Cells migrate through a polyvinylpyrrolidone-free polycarbonate porous 
membrane (8μm pores) pre-coated with gelatine (0.2mg/ml in PBS, 5 days at 4°C). After 
migration (overnight, 37°C), cells adherent to the underside of the membrane, were fixed by 
methanol and stained according to the Diff-Quik kit (Biomap, Milan, Italy). For quantitative 
analysis, 3 random objective fields for each well were counted, using a 20x objective on an 
optical microscope; the mean number of migrating cells was calculated. 
 
MTT  assay 
To evaluate the cell viability, ADSCs were seeded on 24-well plate at the density of 
25×103cells/well. After 24h cells were treated with 100μM APE (Sigma-Aldrich, St. Louis, MO, 
USA) at 24, 48, and 72h. Cells were also treated with muscarinic receptor antagonist (10-7M 
Methoctramine, 10-7M Pirenzepine  and 10-8M 4-DAMP; Sigma-Aldrich, St. Louis, MO, USA) 
2h before APE treatment. Cell growth was assessed by colorimetric assay based on 3-(4,5-
dimethyl thiazol 2-y1)-2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, 
USA). For each well, the OD at 570 nm was measured by GloMax Multi Detection System 
(Promega, Madison, WI, USA). 
 
Flow Cytometry analysis 
The cells were plated on 60-mm diameter dishes at a density of 2x104 cells/dish. The day after 
plating, the cells, excluding control samples, were treated with 100μM APE for 48, 72 and 96h. 
At the end of the treatment, cells were incubated for 90 min with 45µM bromodeoxyuridine 
(final concentration) (BrdU, Sigma-Aldrich), collected by trypsinization, centrifuged for 10min 
at 1,000 rpm and then fixed in methanol/PBS 1:1 (v/v). To identify cells in S phase, DNA 
content and BrdUrd incorporation were determined in simultaneous analysis by staining with 
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propidium iodide (PI) and anti-BrdU respectively. Partial DNA denaturation was performed by 
incubating the cells in 3N HCl for 45 min, followed by neutralization with 0.1 M sodium 
tetraborate. 
Samples were then incubated with monoclonal anti-BrdU (1:50 v/v; Dako, Santa Clara, CA, 
USA; RRID:AB_10013660) for a further 30 min at RT, washed twice with 0.5% Tween-20 in 
PBS and incubated for 30 min with antimouse Alexa 488 fluor-conjugated (1:600) (Promega 
Italia, MI, Italy). Samples were washed twice with PBS plus 0.5% Tween-20 and finally stained 
with 10µg/ml PI for 15 min at RT. Flow cytometry analysis was performed with a flow 
cytometer Coulter Epics XL with 488 nm wavelength excitation and 104 events were collected 
for each sample. Biparametric (DNA content versus BrdU content) analysis were performed 
using WinMDI 2.7 software. 
 
Recovery 
To assess whether inhibition of cell proliferation-APE induced was reversible, a recovery 
analysis was set up. The cells were treated for 96h with APE. Then the medium containing APE 
was eliminated and the cells were washed with PBS and fresh complete medium without APE 
was added. Growth analysis was assessed by MTT assay (Sigma-Aldrich, St. Louis, MO, USA). 
For each well, the OD at 570nm was measured by GloMax Multi Detection System (Promega, 
Madison, WI, USA ), at different time points after 96h of APE  treatment (72-168h). 
 
Cell viability assay 
Cell viability was evalutated by trypan blue staining.  Ten μl of trypan blue solution (1:10 v/v) 
(Sigma-Aldrich, St. Louis, MO, USA) was added to 90μl of cell suspension. After 5 min, the 
number of blue-stained cells (not viable) and unstained cells (viable) was evaluated using 
Bürcker chamber (data not shown). The cell viability was also analysed by LUNA cell Counter 
and the data were presented as percentage of live cells/total cells. 
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Data  analysis 
Data analysis were performed with GraphPad Prism (GraphPad Software Inc, La Jolla, CA, 
USA). Data was presented as the mean ± SEM. Student's t test or one-way ANOVA analysis 
with Bonferroni’ or Tukey’s post tests were used. A value of p < 0.05 was considered 
statistically significant: p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***). The densitometric 
analysis of the RT-PCR and Western blot analysis was measured by ImageJ software (NIH, 
USA: RRID: SCR_003070). 
 
Results 
Expression of stemness markers and muscarinic receptors 
ADSCs are positive for different markers including CD29, CD44, and CD90 (Bobis et al, 2006). 
To validate stemness property, the expression of these stemness markers were determined by 
RT-PCR analysis. The results were compared to fibroblasts, as differentiated cells (Fig.1A). 
These results demonstrated higher levels of stemness markers expression in ADSCs compared 
with differentiated fibroblast population, confirming the stem cell nature of our cultures. Then, 
the muscarinic receptor subtypes expression were characterised by semiquantitative RT-PCR 
analysis. As showed in Fig.1B the ADSCs express the transcripts for several muscarinic receptor 
subtypes (M1-M4), whereas the expression of M5 subtype resulted undetectable. The M2 and 
M3 subtypes appeared the most abundant muscarinic receptors in ADSCs. However, considering 
the well characterized role of M2 receptors in the control of cell proliferation and migration of 
other cell types (Loreti et al, 2007; De Angelis et al, 2012; Uggenti et al, 2014; Alessandrini et 
al, 2015), we focused our attention on the potential effects produced by M2 receptors in ADSCs. 
For this reason, the M2 receptor protein in ADSCs has been also confirmed by Western blot 
analysis (Fig.1C). 
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Positive autoregulation of M2 receptor subtype 
Interistingly, we evaluated whether the M2 activation may induce an autocrine regulation of its 
expression on the ADSCs. To this aim, the ADSCs were treated with the M2 agonist APE 
(100µM). The M2 agonist treatment induces a higher expression of the M2 receptor transcript 
and protein as demonstrated by RT-PCR analysis and immunocytochemistry. This positive 
feedback was corroborated by the use of methoctramine, a preferential M2 antagonist. In fact the 
presence of M2 antagonist counteracted the up-regulated expression of M2 receptors induced by 
APE in ADSCs  (Fig. 2A and 2B). 
 
M2 receptor activation affects ADSCs proliferation 
Thereafter, the ability of M2 muscarinic receptor to modulate ADSCs growth was evaluated by 
MTT assay. To this end, ADSCs were treated with M2 agonist APE that, as demonstrated in our 
previous studies  by pharmacological competition experiments and M2 silencing (Ferretti et al, 
2013; Alessandrini et al, 2015), is able to activate selectively only the M2 receptor. ADSCs were 
treated with 100µM APE for 24, 48 and 72h. As shown in Fig. 3A, the constrast phase light 
microscopy images indicated that ADSCs, in presence of APE, apparently decreased in cell 
number, compared to untreated cells. The MTT assay supported this observation, demonstrating 
that APE treatment significantly impaired ADSCs growth (Fig. 3B).  In order to confirm that this 
effect was mediated by M2 receptors, the cells were treated with APE and M2 antagonist 
methoctramine (10-7M). Moreover ADSCs were also treated with APE 100µM in co-presence of 
pirenzepine (10-7M) and 4-DAMP (10-8M), respectively M1 and M3 antagonists. The results 
obtained indicated that only methoctramine was able to counteract APE effects. In fact in 
presence of methoctramine, APE was not able to decrease ADSCs growth and the number of the 
cells appeared comparable to the untreated cells (Fig. 3B). Conversely, neither pirenzepine nor 
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4-DAMP were able to counterct APE effects (Fig. 3B). The analysis of cell viability indicated an 
apparently decrease of cell survival only after 24h of APE treatment, without any other 
significant change between treated and untreated cells at all time points considered; thus these 
results indicated that the decreased cell number observed after APE treatment was not dependent 
on APE toxicity (Fig. 3C).   
In order to confirm the ability of M2 receptors to inhibit cell proliferation, cell cycle analysis on 
ADSCs maintained in the presence of 100µM APE for 48, 72 and 96 h, was performed. Before 
harvesting, cell cultures were pulsed with BrdU for 90 min to monitor S phase progression. The 
bi-parametric analysis of BrdU labelling versus DNA content, measured by propidium iodide, 
allowed the analysis of cell progression through the G1/S/G2 phases. As shown in Figure 4 and 
Table 2, the ADSCs showed a dramatic decrease in the BrdU labelled cell fraction after APE 
treatment. A decrease in the percentage of cells in the S phase after prolonged treatment was also 
observed with a progressive accumulation of the cells in the G1 phase. 
The inhibition of cell proliferation was also confirmed by analysis of genes involved in cell 
proliferation. The analysis of PCNA and c-jun transcript levels demonstrated that APE treatment 
is able to significantly decrease their levels (Fig. 5A). The Western blot analysis for PCNA 
confirmed the decreased expression of the protein upon APE treatment, according to RT-PCR 
results (Fig. 5B). Similarly also cyclin D1 appeared significantly decreased after APE treatment, 
and the presence of methoctramine was able to re-establish the levels of cyclinD1 to the 
untreated cells (Fig. 5C). Considering the mitogenic effects of PDGF for MSCs (Rodrigues et al, 
2010; Farahani et al, 2015), the basal expression of the PDGFR-ȕ was also analysed in ADSCs. 
The RT-PCR analysis confirmed that ADSCs express PDGFR-ȕ and that APE was able to 
significantly decreased its expression (Fig. 5A). 
Finally, in order to establish whether the cell proliferation was recovered by M2 agonist 
withdrawl, ADSCs were treated with 100μM APE for 96h, then APE was removed and 
subsequently the cell number was assessed from 72 to 168h by MTT assay. After 96h in absence 
of M2 agonist, ADSCs were able to recover the proliferative state, although at lower levels if 
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compared to controls (Fig. 6A). The recovery of cell proliferation was accompained by the 
increased expression of genes involved in cell proliferation such as PDGFR-ȕ and cyclinD1 
(Fig.6B and 6C). 
 
M2 receptors modulate ADSCs migration 
To evaluate the M2 cholinergic agonist effect on cell migration, wound healing technique was 
performed (Fig.7A). When required from experimental plan, the muscarinic antagonists were 
added to the culture medium 2h before APE treatment. The migration was observed after 6h, in 
order to exclude the influence of cell proliferation, although the co-treatment with mitomycin C 
(an anti-tumor drug able to arrest cell proliferation) was also added. Six hours upon APE 
treatment, the distance of the gap between the two fronts was measured in the treated and 
untreated cells and compared respectively with their t0. The results indicated that the presence of 
M2 agonist APE impaired cell migration (Fig. 7A and 7B). The analysis of cell migration was 
also measured in presence of M2 antagonist, methoctramine and pirenzepine plus 4-DAMP, M1 
and M3 antagonists respectively. After M1-M3 antagonists addition, ADSCs migration appeared 
comparable to APE treatment. Conversely, in presence of M2 antagonist methoctramine, the 
effect of APE was abolished and migration appeared comparable to untreated cells (Fig. 7A and 
7B). The inhibitory effect of APE on cell migration was also confirmed by the Boyden's chamber 
assay; in fact the number of cells migrated in the below chamber, where the FBS was added as 
chemioattractant, was decreased in presence of 100µM APE compared with the untreated cells 
(Fig. 7C and 7D). 
 It is known that the CXCL12-CXCR4/CXCR7 axis is involved in migration and/or proliferation  
of several cells, including ADSCs (Li et al, 2013). By semiquantitave RT-PCR analysis, the 
CXCL12, CXCR4 and CXCR7 mRNA expression levels were analysed. After APE treatment, 
CXCR4 and CXCR7 expression were significantly reduced while CXCL12 expression appeared 
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not significantly affected (Fig. 8A). Similarly, Western blot analysis for CXCR4 and CXCR7 
demonstrated a significant decrease of protein levels of the both receptors (Fig. 8B and 8C). 
 
Discussion 
Adipose tissue represents an attractive source of stem cells for regeneration, given their 
multipotentiality and ability to self-renewal. ADSCs can be obtained from various sources, but 
adipose tissue seems to be the most promising considering its availability,  good accessibility and 
poor invasiveness in collecting. These cells have a great potential since can be amplified and 
differentiated in vitro in cells strains and transplanted to promote regeneration of several 
damaged tissues (Caddick et al, 2006; Kingham et al, 2007; Faroni et al, 2015). 
ACh plays important roles in non-neural tissues, controlling proliferation, differentiation and 
migration in several cell types such as neural precursors cells, keratinocytes, lymphocytes and 
lung epithelial cells (Ma et al. 2000, Skok et al, 2006; Hoogduijn et al, 2009; Asrican et al 2016).  
However, no clear evidence on the role of ACh and its receptors in MSCs  has bee reported.  Our 
goal was to assess whether the ADSCs respond to ACh stimuli and which can be the effects 
produced. In this light, the ADSCs isolated from rat adipose tissue were used, confirming the 
stemness property through the analysis of specific markers. The colinoceptivity of these cells 
was then demonstrated by the analysis of the expression of different muscarinic receptor 
subtypes. Our interest was mainly focused on M2 receptors, that was proved to be mainly  
involved in the control of cell proliferation in several cell types (i.e. glial cells, neural precursors) 
(Ma et al, 2000; De Angelis et al, 2012; Loreti et al, 2007). In the ADSCs, M2 was activated by 
the selective agonist APE, a synthetic modified alkaloid derived by a metabolite produced by 
areca nut (Barlow et al, 1985). We previously demonstrated that APE was able to activate 
seletively only the M2 receptors (Loreti et al, 2007; De Angelis et al, 2012; Ferretti et al, 2013, 
Alessandrini et al, 2015). When ADSCs were treated with APE, cell growth as well as the 
expression of several genes involved in cell proliferation were significantly decreased. For 
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instance, c-jun, PCNA and cyclin D1 resulted decreased. Considering that cell viability was not 
affected by APE, M2 receptor activation was proposed as regulator of cell growth. In fact, the 
inhibition of cell proliferation was confirmed by flow cytometry analysis of ADSCs after BrdU 
incorporation. As indicated in table 2, the percentage of cells in S phase was strongly decreased 
upon M2 agonist treatment already at 48h of treatment and it remains substanstially unvariable at 
72 and 96h.  The decreased expression of PDGFR-ȕ after APE treatment, suggested that the 
ability of M2 receptor to reduce cell proliferation may be dependent also on inhibition of 
PDGFR-ȕ expression; this causes a decreased ability of ADSCs to respond to growth factors like 
PDGF-ȕ (Rodrigues et al, 2010; Farahani et al, 2015). Interestingly the selective stimulation of 
M2 receptors appears related to a positive autocrine mechanism, that strength the M2-mediated 
outcomes observed in ADSCs. 
The specific involvement of M2 was further evidenced by using the muscarinic antagonists. 
Indeed,  pirenzepine and 4-DAMP, respectively antagonists of M1 and M3 receptor subtypes, or 
the use of  methoctramine, specific  M2 antagonist, showed that only the latter was able to 
conteract the APE effects, confirming that also in ADSCs, APE binds selectively the M2 
muscarinic  receptor. However, 96h after treatment and withdrawal of M2 agonist, ADSCs 
recover the cell proliferation, albeit maintaining a proliferative rate lower than the untreated 
cells. The proliferation rescue was also confirmed by increased gene expression of proliferation 
markers (i.e. PCNA, cyclin D1).  
The migration is an other important MSCs characteristic. Here we demonstrate that M2 receptor 
activation was also able to inhibit ADSCs migration. In fact, in wound healing experiments, the 
APE-treated cells showed a decreased ability to migrate. Still using M1, M2 and M3 antagonists, 
it was observed that M2 agonist effects was counteracted only by methoctramine (M2 
antagonist) thus demonstrating that M2 receptors negatively modulate ADSCs migration. 
Similarly, by the Boyden chamber assay, we demonstrated that the M2 receptor activation  
affects ADSC migration and the chemotactic ability of the cells to respond to the gradient of 
FBS, used as chemoattractant. In order to explain how M2 receptors impaired the ADSCs 
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migration, the ability of M2 receptors to modulate the expression of the CXCL12/SDF1-
CXCR4/CXCR7 axis was also analysed. Both receptors are expressed in ADSCs, in particular 
after stimulation with SDF1. However, while CXCR4 appeared involved in the modulation of 
cell migration, the CXCR7 mediates the SDF-1 mitogenic effects on ADSCs (Li et al, 2013; 
Marquez and Wieczorek, 2013). In our experimental condition we demonstrated that APE 
negatively modulate the expression of CXCR4 and CXCR7 expression, both at mRNA and 
protein levels. The expression of SDF1-CXCL12, instead, was not modified by M2 agonist 
treatment. Our data suggest that M2 receptor activation negatively influence the effects mediated 
by SDF-1/CXCL12: preventing the chemokine’ binding; in particular the decreasing of the 
CXCR4 expression may thus inhibit cell migration while the reduced expression of CXCR7, 
toghether with the reduced levels of PDGFR-, may negatively influence the ADSCs 
proliferation.  
In conclusion, our data demonstrate that ADSCs are cholinoceptive cells, responsive to M2 
receptors selective activation. The activity of this receptor may contribute to maintain the stem 
cell pool in quiescent status, inhibiting, in reversible manner, the proliferative state and blocking 
cell migration. In agreement, these has been observed also for neural precursors in which, the 
M2 mediated mechanisms, control cell proliferation and differentiation (Ma et al, 2000). In these 
context, in particular for ADSCs, the modulated expression of PDGFR-ȕ and CXCR7 receptors 
by Mβ receptor activity may impair the action of growth factors such as PDGF-ȕ and SDF-
1/CXCL1β, balancing the quiescent phase of ADSCs with the proliferative, migratory and 
differentiated phases. These findings may open new interesting perspectives on the control of 
ADSCs proliferation/differentiation overall for their use in regenerative medicine.  
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Figure Legends 
Figure 1.  Stemness markers and muscarinic receptor subtypes expression.  
A) Stemness marker expression was assessed by RT-PCR. Fibroblasts was used as control of 
differentiated cells. B) RT-PCR  analysis shows ADSCs expressing all muscarinic receptors, 
except M5. In particular Mβ and Mγ expression appears more prominent. GAPDH was used as 
housekeeping gene. C) Western Blot shows M2 muscarinic receptors expression; rat brain was 
used as positive control. ȕ-actin was used as protein reference. 
 
Figure 2.  Positive feedback of M2 receptor expression.  
A) RT-PCR analysis of Mβ receptors in ADSCs in absence or presence of Mβ agonist (APE). Mβ 
antagonist methoctramine (Meth) was used to conteract the APE effects. The graphs show the 
densitometric analysis of the band normalized for the housekeeping GAPDH. The results are the 
media ± SEM obtained from three independent experiments. B) Immunocytochemistry analysis 
for Mβ receptor in ADSCs in absence or presence of APE and APE plus methoctramine (β00x). 
 
Figure 3. The activation of M2 receptors causes an inhibition of cell growth 
A) ADSCs cultures shows a flattened fibroblast-like morphology. Cells treated with APE appears 
at  lower density compared to untreated cells (100x). B) Analysis of cell growth by MTT assay 
upon100μM APE treatment. Mβ agonist causes a decreased cell growth in time dependent 
manner. The cell proliferation has been also evaluated in cultures maintained in the presence of 
100μM APE plus M1 and Mγ antagonists (10-7M Pirenzepine; (Pire), 10-8M 4-DAMP, 
respectively) and 100μM APE plus Mβ antagonists (10-7M Methoctramine; Meth). The presence 
of the M1 and Mγ antagonists does not counteract the Mβ agonist effects, demonstrating that 
these receptors are not involved in the APE inhibition of the cell growth. Instead, Meth, a 
preferring Mβ antagonist, is able to counteract the APE effects. C) APE treatment does not 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
influence cell viability. The results are the media ± SEM of three independent experiments 
performed in triplicate. (* p<0.05; ** p< 0.01; ***p<0.001). 
 
Figure 4.  Flow cytometry analysis of ADSCs after BrdU incorporation.  
Bivariate analysis of BrdU incorporation (ordinate) and DNA content (abscissa) in ADSCs  at 
48, 72, 96h in untreated (ctrl) and 100μM APE treated cells. The BrdU labelled cell fraction 
appears dramatically reduced after APE treatment (S phase) (pink area). 
 
Figure 5. The selective activation of M2 receptors causes an inhibition of cell proliferation 
markers 
A) RT-PCR expression analysis of cell proliferation markers in ADSCs upon 100µM APE. 
According to MTT analysis, APE treatment causes a significant decrease of cyclinD1, PCNA, c-
jun, PDGFR-ȕ trascripts. The graphs indicated the densitometric analysis of the bands obtained 
in three independent experiments, normalized for GAPDH gene.  B) Western Blot and 
densitometric analysis of PCNA protein levels in untreated (ctrl) and 100µM APE treated cells 
(β4 and 48h). ȕ-actin was used as protein reference. (N=3; *p<0.05). C) Mβ receptors activation 
induces an inhibition of cyclinD1 transcript, while the presence of Mβ antagonist, Meth, 
counteracts the APE effects, determining a cyclinD1 expression comparable to control. The 
graph indicates the densitometric analysis of the bands obtained in three independent 
experiments and normalized for GAPDH gene expression, used as housekeeping genes. 
 
Figure 6.  Recovery assay 
A) ADSCs proliferation was assessed after 96h in absence and in presence of APE (100μM), 
then APE was removed and the cell growth was analysed from 7β until 168h by MTT assay. 
After 96h ADSCs were able to recover the cell proliferation although maintaining a lower 
proliferative rate than control. B) The rescue of cell proliferation was confirmed by the analysis 
of c-jun, pcna, cyclinD1 and PDGFR-ȕ transcripts. All mRNA levels appear increased after APE 
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removing from the cell culture. C) the graphs indicate the densitometric analysis of the RT-PCR 
analysis. The GAPDH was used as housekeeping gene. The results are the media ± SEM of three 
independent experiments performed in triplicate. (* p<0.05; ** p< 0.01; ***p<0.001). 
 
Figure 7.  Analysis of cell migration   
A) The analysis of cell migration was performed by wound healing assay. The images  have 
been obtained at time 0 (t0) corresponding to time in which the scratch has been performed, and 
after 6h (t6), to analyse the width of scratch in absence or presence of Mβ agonist and 
antagonists (50x). B) the graph indicates the size of the scratch at all the experimental conditions. 
C) Boyden Chamber’assay:  Microscopic images of ADSCs cultures, exposed to 100µM APE, in 
which the migrated cells were stained in purple (150x). D) 24h exposure of ADSCs to 100µM 
APE decreased significantly (**p<0.01) the migration versus a chemotactic agent FBS 1%. 
Migrating cell number (per area in squared mm) of ADSC exposed (grey column) was calculated 
and compared with the controls (Ctrl, white column). The values are means ± SEM. (N=9). (** 
p< 0.01; ***p<0.001). 
Figure 8. Analysis of CXCL12-CXCR4/CXCR7 axis 
A) RT-PCR analysis of CXCL1β, CXCR4 and CXCR7 expression after 100µM APE treatment. 
The graphs below indicate the densitometric analysis of the bands normalized with GAPDH, 
used as housekeeping gene. The results are the media ± SEM of three independent experiments. 
(* p<0.05; ** p< 0.01; ***p<0.001). B) Western Blot and densitometric analysis for CXCR4 
protein in untreated (ctrl) and APE (100µM) treated cells (β4 and 48 h). ȕ-actin was used as 
protein reference (N=3) (*p< 0.05; **p<0.01). C) Western Blot and densitometric analysis for 
CXCR7 protein in untreated (ctrl) and APE (100µM) treated cells (β4 and 48 h). ȕ-actin was 
used as protein reference (N=3) (*p< 0.05; **p<0.01). 
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Table 1. Primers sequences used in semiquantitative RT-PCR analysis 
Primers sequences           Forward          Reverse 
 (RT-PCR) 
 
M1 
 5’-CCATGGAGTCCCTCACATCCT-3’  5’-ATCTACCATGGGCATCTTGATCA-3’ 
M2 5’-GCTCCAATGATTCGACGTCA-3’ 5’-CGAAGTGGAAACTGTTGTTTTCAT-3’ 
M3 5’-TCCATCCTCAACTCTACCAAGCT-3’ 5’-TTGTGAGCATTTCTCTCCACATC-3’ 
M4 5’-CACTCTGCAATGCCACTTTCAA-3’ 5’-CTGTGCCGATGTTCCGATACT-3’ 
M5 5’-ACCCGCACTGAAAACAGTGACT-3’ 5’-ATCGGAACTAGGCAACACACTT-3’ 
cyclinD1 5’-CCCTCTGCACGCACTTGAAG-3’ 5’-GCGAGCCATGCTTAAGACTGA-3’ 
pcna 5’-GAAGCACCAAATCAAGAGAA-3’ 5’-TCACCCCGTCCTTTGCACAG-3’ 
CD29 5’-TGGGTCGCTGATTGGCTG-3’ 5’-CTCTTCAGTGACTGCAAAAATCG-3’ 
CD44 5’-TCATGTTAGAGCATCCGTGC-3’ 5’-GGGTTGTACATCATGCCTCC-3’ 
CD90 5’-TGAACCCAGTCATCAGCAT-3’ 5’-CAGTCGAAGGTTCTGGTTCACC-3’ 
c-jun 5’-GATGGAAACGACCTTCTACGAC-3’ 5’-AGCGTATTCTGGCTATGCAGTT-3’ 
CXCL-12 5’-TGCATCAGTGACGGTAAGCCA-3’ 5’-ATCCACTTTAATTTCGGGTCAA-3’ 
CXCR-4 5’-GCCATGGCTGACTGGTACTT-3’ 5’-GATGAAGGCCAGGATGAGAA-3’ 
CXCR-7 5’-GGCTACGACACACACTGCTA-3’ 5’-GGTCCACGCTCATGCATGCG-3’ 
Pdgfr-β 5’-CAACATTTCGAGCACCTTTGT-3’ 5’-AGGGCACTCCGAAGAGGTAA-3’ 
gapdh 5’-GTGCCAGCCTCGTCTCATAG-3’ 5’-TGATGGCAACAATGTCCACT-3’ 
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    Table 2. Percentage of cells in G1, S, G2/M phases after 100 µM APE treatment.  
   The data are the mean ±SEM. P values are also reported (APE treated cells vs ctrl) 
 
 
G1 (%) SEM P S (%) SEM P  G2/M SEM 
Ctrl 48h 80,05 2   9,29 0,7   9,76 2 
APE 48h 91,3 2,1 0,05 0,71 0,1 0,001 7,36 2,36 
Ctrl 72h 75,05 0,3   10,27 0,1   9,32 3,5 
APE 72h 88,9 0,1 0,01 0,8 1,5 0,001 6,5 3,1 
Ctrl 96h 75,59 4   6,115 1,4   10,06 3,1 
APE 96h 92,045 1,1 0,001 0,67 0,1 0,001 5,85 2,1 
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